Lonial S, Harvey RD, Francis D, Gul E, Jagannath S, Farag S, Hoth D, Frumento R, Garlich JR, Trudel S. "Preliminary Results of a Phase I Study of the Pan-PI3 Kinase Inhibitor SF1126 in Patients with Relapsed and Refractory Myeloma " 2009 American Society of Hematology Annual Meeting abstract #3879.
Ozbay, T., Durden, D.L., Liu, T. "In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells" Cancer Chemotherapy and Pharmacology, published online July 28, 2009.
E. G. Chiorean, D. Mahadevan, W. B. Harris, D. D. Von Hoff, A. E. Younger, D. M. Rensvold, C. F. Shelton, B. T. Hennessy, J. R. Garlich, R. K. Ramanathan; "Phase 1 evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors", poster at ASCO Annual Meeting May 29-June 2 2009, Orlando FL.
Ebenezer David, Benjamin Barwick, Xiaodong Peng, Jonathan Kaufman, Joseph Garlich, The MMRC Team, Sagar Lonial; "SF1126, A Novel PI3K Inhibitor Results in Downstream Inhibition of the PI3K Axis and Displays Sequence Specific Synergy when Combined with Bortezomib in Multiple Myeloma Cells", XIIth International Myeloma Workshop, February 26-March 1, 2009, Washington DC.
Xiaodong Peng, Jingdong Su and Joseph Garlich. Inhibition of Bv8, VEGF, and IGF mediated signaling by the PI3k inhibitor SF1126. 7th International targeted therapies in cancer, Washington DC, August 22-24, 2008.
"Phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of SF1126 a vascular targeted pan-phosphoinositide 3-kinase (PI3K) inhibitor in patients with solid tumors" Annual Meeting of the American Society of Clinical Oncology; May 30-June 3 2008; Abstract accepted for publication
Joseph R. Garlich, Jingdong Su, Xiaodong Peng. Combination Effects of Sirolimus with the Vascular Targeted PI3K Inhibitor SF1126 AACR 99th Annual Meeting, San Diego, CA
Garlich, J.R., De, P., Dey, N., Su, J., Peng, X., Miller, A., Murali, R., Lu, Y., Mills, G.B., Kundra, V., Shu, H., Peng, Q. Durden, D.L. "A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity". Cancer Res. 2008 Jan 1; 68(1):206-15.
Xiaojing Wang, Shuhong Zhang, Xiaodong Peng, Joe Garlich, Li Chen, Jing Liang, Sherif Farag, A Novel Pan-PI3K/Akt Inhibitor, SF1126 Inhibits In Vitro Growth of Multiple Myeloma Cells; joint submission Emory and Semafore; 49th Annual Meeting of the American Society for Hematology (ASH, December 8-11, 2007, Atlanta Georgia (published in Blood as abstracts only: abstract4785)
Harvey RD, Lonial S. "PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma." Future Oncol. 2007 Dec;3(6):639-47. Review.
Xiaodong Peng, Jingdong Su, Joseph R. Garlich. Combination Effects of SF1126, A Vascular Targeted PI3 Kinase Inhibitor ACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics), San Francisco, CA
Xiaodong Peng, Jingdong Su, Joseph R. Garlich. Initial Combination Studies of the PI3K Inhibitor SF1126 in Prostate Cancer Cell Lines. Prostate Cancer Foundation 14th Annual Scientific Retreat, Lake Tahoe, Nevada
S.K. Peirce, D.L. Durden, J.R. Garlich, H.W. Findley. SF1126, a novel pan-PI3K inhibitor, inhibits activation of Mdm2 and increases sensitivity to doxorubicin in wild type p53 neuroblastoma cell lines”. American Association of Cancer Research (AACR) 98th Annual Meeting, Los Angeles, CA
Qiong Peng, Pradip De, Nandini Dey, Chengyu Prince, Joseph Garlich and Donald L. Durden. Preclinical studies of a pan PI3K inhibitor (SF1126) in renal cell carcinoma. American Association of Cancer Research (AACR) 98th Annual Meeting, Los Angeles, CA